期刊论文详细信息
Stem Cell Research & Therapy
Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?
Fernanda de Macêdo Lima1  André Luiz Nunes Gobatto1  Luciana Souza de Aragão França2  Zaquer Suzana Munhoz Costa-Ferro2  Carolina Kymie Vasques Nonaka2  Kátia Nunes da Silva3  Bruno Raphael Ribeiro Cavalcante3  Bruno Solano de Freitas Souza3  Alex Cleber Improta Caria4  Miquéias Lopes-Pacheco5  Patricia Rieken Macêdo Rocco5 
[1] Center for Biotechnology and Cell Therapy, São Rafael Hospital;D’Or Institute for Research and Education (IDOR);Goncalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ);Graduate Program in Medicine and Health, Faculty of Medicine, Federal University of Bahia;Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro;
关键词: COVID-19;    Cell therapy;    Mesenchymal stromal cells;    Acute respiratory distress syndrome;    SARS-CoV-2;   
DOI  :  10.1186/s13287-021-02502-7
来源: DOAJ
【 摘 要 】

Abstract The COVID-19 pandemic, caused by the rapid global spread of the novel coronavirus (SARS-CoV-2), has caused healthcare systems to collapse and led to hundreds of thousands of deaths. The clinical spectrum of COVID-19 is not only limited to local pneumonia but also represents multiple organ involvement, with potential for systemic complications. One year after the pandemic, pathophysiological knowledge has evolved, and many therapeutic advances have occurred, but mortality rates are still elevated in severe/critical COVID-19 cases. Mesenchymal stromal cells (MSCs) can exert immunomodulatory, antiviral, and pro-regenerative paracrine/endocrine actions and are therefore promising candidates for MSC-based therapies. In this review, we discuss the rationale for MSC-based therapies based on currently available preclinical and clinical evidence of safety, potential efficacy, and mechanisms of action. Finally, we present a critical analysis of the risks, limitations, challenges, and opportunities that place MSC-based products as a therapeutic strategy that may complement the current arsenal against COVID-19 and reduce the pandemic’s unmet medical needs.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:1次